NCT07091617 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
| NCT ID | NCT07091617 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Alliance for Clinical Trials in Oncology |
| Condition | Miscellaneous Neoplasm, Nos |
| Study Type | INTERVENTIONAL |
| Enrollment | 535 participants |
| Start Date | 2025-12-10 |
| Primary Completion | 2028-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 535 participants in total. It began in 2025-12-10 with a primary completion date of 2028-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard evidence-based practice and can inform enhanced screening and risk reducing measures to reduce cancer morbidity and mortality. Despite this, many AYAs are not receiving recommended genetic counseling and testing. Offering remote telehealth services can address access barriers and chatbots and texting interventions could enhance patient outcomes and reduce provider and staff time. The use of a digital chatbot enabled intervention may be equally as effective as standard remote genetic services in AYA cancer patients undergoing genetic testing.
Eligibility Criteria
* PATIENTS: Age ≥ 18 years and ≤ 39 years at the time of enrollment * PATIENTS: AYA cancer patients and survivors. This includes patients at any stage of diagnosis (e.g., newly diagnosed, in treatment, in survivorship) and a cancer diagnosis (including pediatric cancers) at any age ≤ 39 years old. Given targeted therapies for BRCA+ and microsatellite instability (MSI)-high/Lynch Syndrome patients and benefit to relatives, patients with metastatic cancer are included. Any history of cancer, regardless of being in treatment or not * PATIENTS: Language: In order to complete the mandatory patient-completed measures and receive genetic education and counseling, participants must be able to speak and read English or Spanish * PATIENTS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members * PATIENTS: No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician * PATIENTS: Participants must meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing assessment provided by Penn Telegenetics by the Eligibility Verification Assessment (EVA) chatbot, or paper forms and genetic counselor's review * NON-PATIENT PARTICIPANT: Non-patient participants eligible for this study include: oncology providers, members of the care team and clinic staff, genetic counselors, and insurers (i.e., people who work in financial services and/or for insurance companies) who participate in oncology care among AYA in community for this study * NON-PATIENT PARTICIPANT: Age ≥ 18 years * NON-PATIENT PARTICIPANT: Non-patient participants must be able to speak and read English or Spanish in order to participate in the key informant interviews
Contact & Investigator
Angela Bradbury, MD
STUDY CHAIR
Alliance for Clinical Trials in Oncology
Frequently Asked Questions
Who can join the NCT07091617 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Miscellaneous Neoplasm, Nos. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07091617 currently recruiting?
Yes, NCT07091617 is actively recruiting participants. Contact the research team at cancercontrolprotocols@alliancenctn.org for enrollment information.
Where is the NCT07091617 trial being conducted?
This trial is being conducted at Anchorage, United States, Anchorage, United States, Anchorage, United States, Anchorage, United States and 11 additional locations.
Who is sponsoring the NCT07091617 clinical trial?
NCT07091617 is sponsored by Alliance for Clinical Trials in Oncology. The principal investigator is Angela Bradbury, MD at Alliance for Clinical Trials in Oncology. The trial plans to enroll 535 participants.